Table 1.
Patient and tumor characteristics (N=413).
| Characteristics | Right–sided | Left–sided | P–value | ||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Age, median (range) | 61 (29–93) | 62 (29–83) | 61 (29–93) | ||||
| Gender | |||||||
| Female | 154 | 37.3 | 31 | 44.3 | 123 | 35.9 | 0.18 |
| Male | 259 | 62.7 | 39 | 55.7 | 220 | 64.1 | |
| Metastatic site | |||||||
| Liver | 319 | 77.2 | 53 | 75.7 | 266 | 77.6 | 0.74 |
| Lung | 175 | 42.4 | 34 | 48.6 | 141 | 41.1 | 0.25 |
| Peritoneal | 64 | 15.5 | 19 | 27.1 | 45 | 13.1 | 0.003 |
| Non regional lymph nodes | 97 | 23.5 | 20 | 28.6 | 77 | 22.4 | 0.27 |
| Bone or other | 43 | 10.4 | 8 | 11.4 | 35 | 10.2 | 0.76 |
| Metastatic type | |||||||
| Synchronous | 251 | 60.8 | 42 | 60 | 209 | 60.9 | 0.88 |
| Metachronous | 162 | 39.2 | 28 | 40 | 134 | 39.1 | |
| Histology | |||||||
| Adenocarcinoma | 397 | 96.1 | 65 | 92.9 | 332 | 96.8 | 0.45 |
| Mucinous | 9 | 2.2 | 3 | 4.3 | 6 | 1.7 | |
| Signet–ring cell | 7 | 1.7 | 2 | 2.9 | 5 | 1.5 | |
| Differentiation | |||||||
| Well | 69 | 16.7 | 12 | 17.1 | 57 | 16.6 | 0.54 |
| Moderately | 277 | 67.1 | 46 | 65.7 | 231 | 67.3 | |
| Poorly | 30 | 7.3 | 8 | 11.4 | 22 | 6.4 | |
| No data | 37 | 8.9 | 4 | 5.7 | 33 | 9.6 | |
| MMR status | |||||||
| pMMR | 68 | 16.5 | 12 | 17.1 | 56 | 16.3 | 0.001 |
| dMMR | 3 | 0.7 | 3 | 4.3 | 0 | 0 | |
| No data | 342 | 82.8 | 55 | 78.5 | 287 | 83.7 | |
| Line of treatment | |||||||
| Second–line | 132 | 32 | 25 | 35.7 | 107 | 31.2 | 0.17 |
| Third–line | 238 | 57.6 | 42 | 60 | 196 | 57.1 | |
| Later–line | 43 | 10.4 | 3 | 4.3 | 40 | 11.7 | |
| Anti–EGFR Ab | |||||||
| Cetuximab | 362 | 87.7 | 68 | 97.1 | 294 | 85.7 | 0.005 |
| Panitumumab | 51 | 12.3 | 2 | 2.9 | 49 | 14.3 | |
| Chemotherapy (+anti–EGFR Ab) | |||||||
| Capecitabine/5FU | 1 | 0.2 | 1 | 1.4 | 0 | 0 | 0.17 |
| FOLFOX/XELOX | 21 | 5.1 | 3 | 4.3 | 18 | 5.2 | |
| FOLFIRI/XELIRI | 88 | 21.3 | 15 | 21.4 | 73 | 21.3 | |
| Single irinotecan | 303 | 73.4 | 51 | 72.9 | 252 | 73.5 | |
pMMR, proficient mismatch repair; dMMR, deficient mismatch repair; anti–EGFR Ab, anti–epidermal growth factor receptor antibodies; FOLFOX, combination leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin; XELOX, combination capecitabine and oxaliplatin; FOLFIRI, combination leucovorin calcium (folinic acid), fluorouracil, and irinotecan hydrochloride; XELIRI, combination capecitabine and irinotecan.
A p–value < 0.05 indicates statistical significance.
Bold means Statistically significant.